Pathos raises $237 million at $3 billion valuation with BMS leading round
Pathos, an artificial intelligence-driven drug development company, said Friday it has raised $237 million in a Series E round led by Bristol Myers Sq
Bristol Myers Squibb
Every Fin-node story mentioning Bristol Myers Squibb — 8 stories, newest first.
Bristol Myers Squibb · 8 stories
Bristol Myers value play versus Lilly growth engine
Bristol Myers Squibb and Eli Lilly posted fiscal 2025 results that confirm the market’s split verdict: one a deep-value dividend stock stabilizing aft
AstraZeneca-Bristol Myers merger talk collapses under weight of its own logic
AstraZeneca shares fell roughly 9 percent early this month after the Financial Times reported the U.K. drugmaker was close to a merger with Bristol My
AstraZeneca BMY Merger Talk Triggers Selloff
AstraZeneca shares fell roughly 9 percent after the Financial Times reported the U.K. drugmaker was close to merging with Bristol Myers Squibb in a de
Novo Nordisk drops 10% as heart drug fails in Phase III
Novo Nordisk shares fell 10% last week after its experimental cardiovascular drug ziltivekimab failed to prevent heart attacks, strokes or cardiovascu
Pfizer beats adjusted profit, raises savings target to $9.7 billion
Pfizer reported an adjusted profit of 77 cents a share, nine cents above estimates, while raising its cumulative cost-savings target to $9.7 billion t
Dow Hits Record on Iran Talks Optimism
The Dow Jones Industrial Average closed at a record high Monday as optimism around U.S.-Iran talks lifted sentiment, though the session's sector rotat
AstraZeneca shares fall on BMS merger talks
AstraZeneca shares dropped 6.1 per cent to 11,860p in early London trading on Monday after the Financial Times reported the UK drugmaker has held talk